arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

download Export Data

Connect Biopharma Holdings Ltd

CNTB

$2.21 ▲ +0.03 (+1.38%) at close

12 Visible periods

25 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

Connect Biopharma Holdings Ltd faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $125.0M

Dividend Yield —

Revenue Growth None

Op. Margin None

ROIC -46.1% ↘

FCF / Share $-0.28

Trailing P/E —

Price / Book 3.3x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Aug 7, 2026.

12-Year Financial Trajectory

Quarterly

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$169.00K

— —

Net Income Profit after all expenses

$-19.40M

↓ -88.8% —

FCF / Share Free cash flow per share

$-0.28

↓ -56.0% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓

Cash Quality ↑

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 4 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q4 FY2021 Dec 31, 2021 20-F ↗
Revenue Growth YoY (%)	—	N/M	-98.7% Weak Weak Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-1334%)	-99.8% Weak Weak Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-1348%)	—	—	—	—	—	—	—	—
EPS Growth YoY (%)	-78.9% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	-68.7% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	-34.8% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	N/M	-18.8% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	—	—	—	—	—	—	—
Net Income Growth YoY (%)	-88.8% Weak ↓ Weak Declining Year-over-year change in net income	-69.6% Weak ↓ Weak Declining Year-over-year change in net income	-18.2% Weak → Weak Stable Year-over-year change in net income	-18.2% Weak Weak Year-over-year change in net income	-18.2% Weak Weak Year-over-year change in net income	—	—	—	—	—	—	—
FCF Growth YoY (%)	-56.0% Weak ↓ Weak Declining Year-over-year change in free cash flow	—	-31.5% Weak ↑ Weak Improving Year-over-year change in free cash flow	-60.6% Weak Weak Year-over-year change in free cash flow	-1591.2% Weak Weak Year-over-year change in free cash flow	—	—	—	—	—	—	—

💰 Are margins durable? 5 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q4 FY2021 Dec 31, 2021 20-F ↗
Operating Margin (%) (%)	—	—	—	—	—	—	—	56.6% Excellent Excellent Operating income as a percentage of revenue Optimal: > 15% vs Sector: Above avg (+277%)	—	—	—	—
Effective Tax Rate (%) (%)	-0.2% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.2% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.4% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.4% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.5% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	-1.2% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.4% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.2% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.3% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—	—	—
Profit Margin (%) (%)	—	—	—	—	—	—	—	-36.0% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-400%)	—	—	—	—
FCF Margin (%) (%)	—	—	—	—	—	-377.1% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	—	-33.1% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	—	—	—	—
FCF / Net Income (x)	0.83x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.75x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	1.70x Excellent ↑ Excellent Improving Free cash flow relative to reported net income Optimal: > 1x	1.26x Good ↑ Good Improving Free cash flow relative to reported net income Optimal: > 1x	0.98x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.30x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	1.51x Excellent ↑ Excellent Improving Free cash flow relative to reported net income Optimal: > 1x	0.92x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	0.07x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	—	—	—

🎯 Is capital allocation efficient? 3 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q4 FY2021 Dec 31, 2021 20-F ↗
Return on Invested Capital (%)	-46.1% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-37.1% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-32.0% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-18.9% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-13.9% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-10.6% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-13.8% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	12.3% Good Good Return earned on debt + equity capital invested Optimal: > 10%	-13.5% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	—	—	—
Return on Capital (%) (%)	-32.6% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-27.7% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-26.2% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-16.2% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-12.4% Weak Weak Operating profit relative to total assets Optimal: > 10%	-9.5% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—	—	—	—	—
Return on Common Equity (%) (%)	-45.5% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-403%)	-36.0% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-340%)	-18.6% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-224%)	-14.4% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-196%)	-12.4% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-183%)	-9.7% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-164%)	-8.6% Weak → Weak Stable Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-158%)	-7.8% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-152%)	-9.3% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-162%)	—	—	—

⚖️ Is the balance sheet risky? 1 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q4 FY2021 Dec 31, 2021 20-F ↗
Net Debt (USD)	$-46.03M	$-38.34M	$-37.84M	$-40.63M	$-47.71M	$-78.23M	—	—	—	$-105.66M	—	—

📊 What does each share earn? 6 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q4 FY2021 Dec 31, 2021 20-F ↗
Revenue per Share (USD)	$0.00	—	$0.00	$0.00	—	—	$0.02	$0.44	—	—	—	—
Basic EPS, GAAP (USD)	$-0.34	$-0.27	$-0.31	$-0.23	$-0.19	$-0.16	$-0.23	$0.27	$-0.16	—	—	—
Free Cash Flow per Share (USD)	$-0.28	—	$-0.31	$-0.23	$-0.18	—	$-0.24	$-0.14	$-0.01	—	—	—
Book Value per Share (USD)	$0.68	$0.74	$0.99	$1.28	$1.50	$1.67	$1.82	$2.01	$1.70	$1.84	—	—
Tangible Book Value per Share (USD)	$0.68	$0.74	$0.99	$1.28	$1.50	$1.67	$1.82	$2.01	$1.70	$1.84	—	—
Basic Weighted Avg Shares (shares)	56.55M	—	55.72M	55.50M	55.35M	—	55.25M	55.19M	55.10M	—	—	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q4 FY2021 Dec 31, 2021 20-F ↗
Working Capital (USD)	$37.98M	$37.32M	$51.17M	$67.02M	$79.19M	$88.50M	—	—	—	$97.26M	—	—
Total Equity (USD)	$42.62M	$41.98M	$55.37M	$71.34M	$82.90M	$92.17M	$100.65M	$110.93M	$93.89M	$101.50M	$158.42M	—

📋 What is driving earnings? 4 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q4 FY2021 Dec 31, 2021 20-F ↗
Sales/Revenue/Turnover (USD)	$169.00K	$0.00	$16.00K	$48.00K	—	$698.00K	$1.22M	$24.12M	—	—	—	—
Depreciation Expense (USD)	$164.00K	$181.00K	$179.00K	$171.00K	$173.00K	$158.00K	$176.00K	$162.00K	$164.00K	—	—	—
Net Income, GAAP (USD)	$-19.40M	$-15.11M	$-10.27M	$-10.27M	$-10.27M	$-8.91M	$-8.69M	$-8.69M	$-8.69M	—	—	—
Operating Cash Flow (USD)	$-16.00M	$-11.25M	$-17.41M	$-12.59M	$-9.96M	$-2.32M	$-13.01M	$-7.70M	$-591.00K	—	—	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 5 years · 12 quarters

Connect Biopharma Holdings Ltd

Analytical Summary

12-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare CNTB with peers